About CTI BioPharma

Website
Website
Employees
Employees
201-500 employees View all
Industry
Industry
Biotechnology
Location
Location
3101 Western Ave., #600, Seattle, WA 98121, US
Description
Information
We are a commercial biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. CTI has one FDA-approved product VONJO^TM (pacritinib), a JAK2 and IRAK1, that spares JAK1. VONJO is approved for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 10^9/L. This indication is approved under FDA accelerated approval based on spleen volume reduction. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). CTI is conducting the Phase 3 PACIFICA study of VONJO in patients with myelofibrosis and severe thrombocytopenia as a post-marketing requirement. VONJO^TM is a trademark of CTI BioPharma Corp.

CTI BioPharma Alternatives

Industry
Biotechnology
Industry
biotechnology
Industry
biotechnology
Industry
biotechnology
Industry
biotechnology
Industry
biotechnology
Industry
biotechnology
Industry
Biotechnology
Industry
biotechnology

Frequently Asked Questions about CTI BioPharma

What is CTI BioPharma email format?

The widely used CTI BioPharma email format is {f}{last} (e.g. [email protected]) with 75% adoption across the company.


What is CTI BioPharma customer service number?

To contact CTI BioPharma customer service number in your country click here to find.


Supercharge your
Prospecting &
Outreach with
ContactOut
Supercharge your Prospecting &
Outreach with ContactOut

Search Portal

Find countless prospects outside of LinkedIn fast

Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.

Discover the source of our data

Learn more